Related Experiment Videos
[Clinical studies on cefroxadine in the field of pediatrics (author's transl)]
Insights
Cefroxadine dry syrup effectively treated pediatric respiratory infections and scarlet fever in 59 children. The antibiotic showed a 76.9% bacteriologic response rate and minimal side effects like mild diarrhea.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
- Bacteriology
Background:
- Acute febrile respiratory tract infections are common in children.
- Antibiotic efficacy is crucial for managing pediatric bacterial infections.
- Cefroxadine is a cephalosporin antibiotic with potential applications in pediatric care.
Observation:
- Cefroxadine dry syrup was administered to 59 children (57 with respiratory infections, 2 with scarlet fever).
- Dosage was 40 mg/kg/day, divided into four doses, for approximately 7 days.
- Bacteriological and clinical responses were evaluated for efficacy and safety.
Findings:
- Overall, 76.9% of isolated pathogens (65 strains) showed a good bacteriologic response.
- Clinical response was favorable in 93.2% of patients (55 children).
- Specific pathogen responses included Staphylococcus aureus (100%), Streptococcus haemolyticus (86.4%), Streptococcus pneumoniae (90.0%), and Haemophilus influenzae (47.6%).
Implications:
- Cefroxadine demonstrates significant efficacy in treating common pediatric bacterial infections.
- The drug is well-tolerated, with only mild diarrhea reported in 3 children.
- Further research may explore its use against resistant strains, particularly Haemophilus influenzae.
Abstract:
Cefroxadine dry syrup was administered to 57 children with acute febrile respiratory tract infections and 2 children with scarlet fever in the dose of 40 mg/kg/day q.i.d. for 2 approximately 7 days. 65 strains of organism were isolated as pathogen from the 59 patients, and 50 of the 65 strains (76.9%) showed bacteriologically good responses. Clinically, 55 children (93.2%) had good response. Out of 63 strains isolated from the 57 cases with respiratory infections, 48 strains (76.2%) showed good bacteriological response. As for the type of pathogen, all strains of Staphylococcus aureus, 86.4% of Streptococcus haemolyticus and 90.0% of Streptococcus pneumoniae had good response, but as for Haemophilus influenzae it was only 47.6%. In one child, Streptococcus pneumoniae appeared during cefroxadine treatment in addition to the preexisting Haemophilus influenza. From the 4 children having no response for their respiratory infections, H. influenzae were isolated in 3 cases and Streptococcus haemolyticus was isolated in 1 case, before starting the treatment. As for side effects, mild diarrhea developed in only 3 children.